Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
3,732,462
-
Share change
-
-161,273
-
Total reported value
-
$12,473,134
-
Put/Call ratio
-
59%
-
Price per share
-
$3.34
-
Number of holders
-
45
-
Value change
-
-$430,534
-
Number of buys
-
11
-
Number of sells
-
21
Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q4 2017
As of 31 Dec 2017,
GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,732,462 shares.
The largest 10 holders included
Vanguard Group Inc, D.A. DAVIDSON & CO., Advisor Group, Inc., BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, Benchmark Capital Advisors, US BANCORP \DE\, NORTHERN TRUST CORP, Neuberger Berman Group LLC, and Geneos Wealth Management Inc..
This page lists
45
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.